In a landmark move for the UK poultry sector, a new field trial to test highly pathogenic avian influenza (HPAI) vaccines in turkeys has begun in England.
The launch at the beginning of March marks what many in the industry say is a pivotal moment in the long-running battle against a disease that has caused severe disruption to both commercial and backyard flocks for many years.
Turkeys are particularly susceptible to avian influenza
The latest phase of research focuses exclusively on turkeys, a species known for its acute susceptibility to HPAI. Past outbreaks have led to rapid onset of clinical signs and high mortality, leaving producers particularly vulnerable. Annual losses attributed to the virus are estimated to reach up to £174 million, affecting government and industry alike.
The trial will involve a small number of birds kept under strict supervision and vaccinated using approved UK and EU vaccines. Currently, vaccination against bird flu is not permitted more widely in the UK, making this targeted exercise a critical opportunity to assess how vaccines might be integrated into future control strategies.